INT181102

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.85
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Epcam)
Anatomy Link Frequency
T-cells 1
Epcam (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 8 98.40 Very High Very High Very High
imagery 1 83.36 Quite High
Inflammatory response 1 51.28 Quite High
cytokine 12 5.00 Very Low Very Low Very Low
abdominal pain 7 5.00 Very Low Very Low Very Low
withdrawal 5 5.00 Very Low Very Low Very Low
anesthesia 5 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
Bile 4 5.00 Very Low Very Low Very Low
nud 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 297 99.84 Very High Very High Very High
Pressure And Volume Under Development 116 98.48 Very High Very High Very High
Toxicity 16 97.28 Very High Very High Very High
Colon Cancer 30 93.40 High High
Breast Cancer 77 90.96 High High
Skin Cancer 4 85.04 High High
Myelodysplastic Syndromes 1 84.48 Quite High
Death 10 81.44 Quite High
Carcinoma 38 81.40 Quite High
Adhesions 20 78.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have developed a simple and highly reproducible IM protocol based on EpCAM antigen recognition [16].
EpCAM Binding (recognition) of
1) Confidence 0.37 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 0.70 Pain Relevance 0
Catumaxomab has binding sites for EpCAM on tumour cells, for CD3 on T-cells, and for Fc?
EpCAM Binding (sites) of in T-cells associated with cancer
2) Confidence 0.29 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2878603 Disease Relevance 0.56 Pain Relevance 0.05
We thus optimized the standard IM technique based on EpCAM antigen recognition.
EpCAM Binding (recognition) of
3) Confidence 0.27 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC549166 Disease Relevance 0.37 Pain Relevance 0
Both monoclonal antibodies recognize specific epitopes of the extracellular domain of the EpCAM molecule. mAb BerEP4 recognizes two (34 kDa and 39 kDa) specific antigens, whereas mAb KS1/4 recognizes one (40 - 42 kDa) specific antigen of the extracellular domain of the EpCAM molecule [10].
EpCAM Binding (recognize) of
4) Confidence 0.23 Published 2010 Journal BMC Biotechnol Section Body Doc Link PMC2868015 Disease Relevance 0.28 Pain Relevance 0
To prevent inhibition of antibody staining by catumaxomab residuals in ascites samples during and after therapy, these samples were stained with the anti-EpCAM antibody VU1D9 (TRION Research, Martinsried, Germany), which recognizes a different EpCAM epitope to HO-3/catumaxomab.
EpCAM Binding (recognizes) of associated with pressure and volume under development
5) Confidence 0.21 Published 2010 Journal International Journal of Cancer. Journal International du Cancer Section Body Doc Link PMC2958458 Disease Relevance 1.07 Pain Relevance 0.04
Once bound to EpCAM via the scFv portion, the fusion construct is internalized through an endocytic pathway.
EpCAM Binding (bound) of
6) Confidence 0.09 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761172 Disease Relevance 0.86 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox